anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized control study that will be completed within the Department of Neurosurgery at Lahey Hospital \& Medical Center. Patients will undergo their recommended surgery to treat single-level lumbar radiculopathy. Patients who are randomized to and consent to receiving a preoperative corticosteroid injection will report to clinic within 2 weeks prior to date of surgery to receive a corticosteroid injection. These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline. To assure the injection is epidural, we will be using loss of resistance technique under fluoroscopy and epidural placement will be confirmed with the live-image instillation in the AP and lateral positions of dye, with pattern confirming epidermal needle placement.

All patients will complete health outcome questionnaires (VAS, EQ-5D, ODI) at baseline (treatment cohort: prior to injection, control cohort: prior to spine surgery), 1 week post-op, 1 month post-op, and 3 months post-op. Patients will be instructed to bring all condition-related pain medication containers to each follow-up for research measuring purposes. Research personnel will record number of pills remaining in container, number of opioid prescription refills, and respective dates. Opioid usage for each subject will be tracked and converted to mg oral morphine equivalents using a standard table. Research personnel will capture additional clinic information such as length of stay, length of time before ambulation, and occurrence of any complications (i.e. DVT, infection). Opioid use, muscle relaxants, and other pain medication use will be followed for 3 months. At baseline and at each post-op follow up, patients will be asked to define their use of illicit drugs over the past 6 months (heroin, cocaine, marijuana, methamphetamine, other). Return to work date and work status will be captured out to 3 months. Patients will submit a health-cost diary at 1 week, 1 month, and 3 months, and this data will be combined with hospital-based cost information to generate a cost analysis. This diary will capture costs such as medication costs, copayments, travel, etc. Additionally, all patient surgery cancelations as well as reason for cancelation will be recorded. No additional medical testing will be required by the patient.
OMICS methods brought significant advancements to the understanding of tumor cell biology, which transformed the treatment and prognosis of several cancers. Clinical practice and outcomes, however, changed significantly less in the case of glioblastoma (GBM). In this study, we aimed to assess the utility of whole exome (WES) sequencing in the clinical setting. Ten pairs of formalin-fixed, paraffin-embedded (FFPE) GBM specimens were obtained at onset (GBM-P) and at recurrence (GBM-R). Histopathological and molecular features of all samples supported the diagnosis of GBM based on WHO CNS5. WES data were filtered, applying a strict and custom-made pipeline, and occurrence of oncogenic and likely oncogenic variants in GBM-P, GBM-R or both were identified by using the VarSeq program version 2.5.0 (Golden Helix, Inc.). Characteristics and recurrence of the variants were analyzed in our own cohort and were also compared to those available in the COSMIC database. The lists of oncogenic and likely oncogenic variants corresponded to those identified in other studies. The average number of these variants were 4 and 5 out of all detected 24 and 34 variants in GBM-P and GBM-R samples, respectively. On average, one shared oncogenic/likely oncogenic variant was found in the pairs. We assessed the identified variants' therapeutic significance, also taking into consideration the guidelines by the Association for Molecular Pathology (AMP). Our data support that a thorough WES analysis is suitable for identifying oncogenic and likely oncogenic variants in an individual clinical sample or a small cohort of FFPE glioma specimens, which concur with those of comprehensive research studies. Such analyses also allow us to monitor molecular dynamics of sequential GBM. In addition, careful evaluation of data according to the AMP guideline reveal that though therapeutic applicability of the variants is generally limited in the clinic, such information may be valuable in selected cases, and can support innovative preclinical and clinical trials.
We wish to determine in a prospective manner whether inorganic nitrate affects the endothelial dysfunction induced by systemic inflammation. At baseline we will measure flow-mediated dilatation (FMD) and peripheral augmentation index, as well as aortic stiffness, as measured by pulse wave velocity (PWV). Volunteers will then receive \~8 mmols of dietary nitrate or nitrate free placebo juice once daily for 6 days. After this, depending on availability, volunteers will receive a typhoid vaccine Typherix®, GlaxoSmithKline UK or Typhim Vi ™, AAH Pharmaceuticals Ltd). This vaccine generates a mild systemic inflammation that is associated with vascular dysfunction. All vascular function measures will be repeated at 8 hours and 32 hours after vaccine administration.
<P>PROBLEM TO BE SOLVED: To provide an exothermic composition having excellent dispersion stability of zeolite and an exothermic cosmetic having excellent usability without settling the zeolite during preservation and without requiring shaking stirring during use and further excellent beauty culture effects and to provide a method for beauty culture caring and a method for stabilization in order to stably disperse powder in the composition.  <P>SOLUTION: The exothermic composition comprises the zeolite (A), a dihydric alcohol (B) and a polyhydric alcohol (C) having three or more hydroxy groups, a hydroxide (D) of an alkaline earth metal and a surfactant (E). The cosmetic comprises the composition. The method for beauty culture caring comprises using the cosmetic. The method for stabilization comprises stably dispersing at least one kind of powder in a substantially nonaqueous medium containing the polyhydric alcohol. In the method, the medium contains at least the one kind of the hydroxide (D) of the alkaline earth metal and the surfactant (E).  <P>COPYRIGHT: (C)2004,JPO
Serum quinidine levels can be conveniently assayed and monitored, but the electrocardiographic QT interval is a better predictor of quinidine-induced ventricular arrhythmias. C

The necessary treatment of hemodynamically unstable polymorphic ventricular tachycardia (including ) is withdrawal of treatment with quinidine and either immediate cardioversion or, if a cardiac pacemaker is in place or immediately available, immediate overdrive pacing. After pacing or cardioversion, further management must be guided by the length of the QT interval. torsades de pointesC

Quinidine-associated ventricular tachyarrhythmias with normal underlying QT intervals have not been adequately studied. Because of the theoretical possibility of QT-prolonging effects that might be additive to those of quinidine, other antiarrhythmics with Class I (disopyramide, procainamide) or Class III activities should (if possible) be avoided. Similarly, although the use of bretylium in quinidine overdose has not been reported, it is reasonable to expect that the α-blocking properties of bretylium might be additive to those of quinidine, resulting in problematic hypotension. C

If the post-cardioversion QT interval is prolonged, then the pre-cardioversion polymorphic ventricular tachyarrhythmia was (by definition) In this case, lidocaine and bretylium are unlikely to be of value, and other Class I antiarrhythmics (disopyramide, procainamide) are likely to exacerbate the situation. Factors contributing to QT prolongation (especially hypokalemia, hypomagnesemia, and hypocalcemia) should be sought out and (if possible) aggressively corrected. Prevention of recurrent may require sustained overdrive pacing or the cautious administration of isoproterenol (30 to 150 ng/kg/min). Ctorsades de pointes.Ctorsades
Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
Silicosis is a systemic disease with predominantly diffuse fibrosis of the lungs due to prolonged inhalation of free SiO2 dust during the manufacturing process, for which there is no effective treatment. In this study, we used a combined epigenetic and transcriptomic approach to reveal the chromatin-opening features of silicosis and identify the key transcription factor activator protein 1 (AP-1) that responds to silicosis fibrosis. Therapeutic administration of an AP-1 inhibitor inhibits the PI3K/AKT signaling pathway, reduces fibrosis marker proteins, and significantly ameliorates lung fibrosis in a mouse model of silicosis. In addition, it was observed that the expression of Jun and JunB was significantly up-regulated in a TGF-β1-induced in vitro transdifferentiation model of NIH/3T3 cells, and Co-IP confirmed that a protein complex could be formed between Jun and JunB. Mechanistically, silencing of Jun and JunB expression reversed the activation of the PI3K/AKT signaling pathway and the upregulation of fibrosis marker proteins in NIH/3 T3 cells after TGF-β1 stimulation. Taken together, Jun/JunB is expected to be a potential therapeutic target for silicosis fibrosis.
BACKGROUND: Primary aldosteronism (PA) is associated with increased metabolic risks. However, controversy exists as to which subtype of PA has a higher metabolic risk between bilateral and lateralized PA. This study aimed to assess the body composition of 2 PA subtypes, bilateral PA and lateralized PA, according to sex and autonomous cortisol secretion (ACS) and their contribution to comorbidities.
DESIGN AND METHODS: A total of 400 patients with PA (females, n = 210) and 1:10 age- and sex-matched healthy controls (n = 4000) were enrolled. The skeletal muscle area (SMA), subcutaneous fat area, and visceral fat area (VFA) at the third lumbar spine were calculated using abdominal computed tomography-based body composition analysis.
RESULTS: Patients with bilateral PA had higher body mass index (BMI) in both sexes (all P < .05). Hemoglobin A1c level and the prevalence of diabetes were higher in female patients with bilateral PA than in those with lateralized PA (all P < .05). The VFA/BMI ratio was significantly higher in bilateral PA patients than in lateralized PA patients (5.77 ± 2.69 vs 4.56 ± 2.35 in men; 4.03 ± 2.58 vs 2.53 ± 2.05 in women, all P < .001). PA patients with ACS showed decreased SMA compared to those without ACS. Compared with healthy controls, all patients with bilateral PA and female patients with lateralized PA showed significantly higher VFA and VFA/BMI.
CONCLUSIONS: Patients with bilateral PA were more obese and had higher VFA levels than those with lateralized PA. Despite a milder form of PA, this metabolically unfavorable visceral fat distribution may lead to a higher metabolic risk in patients with bilateral PA.
Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
OBJECTIVE: Despite the wide use of ziconotide in the USA for treating refractory cancer- and noncancer-related pain, this agent is little used in Europe, even if licensed by the European Medicines Agency (EMA). The reason could be attributed to the high, fixed starting dose required for ziconotide, as stated in the EMA Summary of Product Characteristics (SmPC). This dosage recommendation is based on the results of pivotal clinical studies of ziconotide, which utilized aggressive titration schedules. Thus, a reappraisal of the available evidence, as well as a reflection on real-life clinical experiences, might be useful to identify practice adjustments to improve the clinical application of ziconotide in the European scenario. In line with this need, this paper reports some clinical experiences of patients with chronic pain treated with ziconotide intrathecal (IT) therapy in Italy, particularly focusing on long-term treatment to further characterize and improve the use of this agent in real practice. Moreover, a literature review of the available data on the effectiveness and safety of IT ziconotide is provided.
CASE SERIES: Collected clinical experiences suggested that the use of IT ziconotide represents a valuable option, particularly in cases where other treatments have been ineffective or poorly tolerated. Ziconotide was shown to not cause severe side effects in the long-term treatment, leading to a constant pain relief effect at stable doses, without adverse events that caused therapy interruption. The overall constant ziconotide dosages also suggest the absence of a tolerance effect. In parallel, the evidence in the literature aligns with real-world evidence and further supports the use of IT ziconotide as an important option for the management of chronic pain.
CONCLUSIONS: IT ziconotide represents a valuable addition to the armamentarium of pain management strategies, offering hope for improved quality of life for patients suffering from chronic, treatment-resistant pain. Continued research and clinical experience will further elucidate its optimal use and role in comprehensive pain care.
The present invention relates to an anticancer medicinal composition in dietetic therapy and a preparing method thereof. The composition mainly contains bamboo leaves, ginger, arnebia root, mint and fruit juice, wherein the bamboo leaves and the arnebia root are soaked by spirits; the ginger and the mint are soaked by water; supernates on the solutions are extracted and mixed with the fruit juice to prepare a beverage. Patients with cancer take the beverage 3 to 4 times every day, and take 30 to 40 milliliters each time. For healthy people, the beverage can be taken 20 milliliters every day before sleep for cancer prevention and health care. The medicinal composition has the characteristics that the cure rate reaches 36%, and the effective rate reaches over 97%; verified by experiments on animals, the tumor control rate reaches as high as 66.32%, and the medicinal composition is suitable for treating cerebroma, lung cancer, liver cancer, mammary cancer, carcinoma of bladder, esophagus cancer, colorectal cancer, pediatric leukemia, etc. The medicinal composition cured more than 100 patients, and the medicinal composition no toxic or side effect, convenient taking and low price. Patients taking the medicinal composition do not need to live in hospital. The present invention has good economical and social benefits.
Hip arthroplasty is a common procedure with high costs and difficult rehabilitation. It causes postoperative pain, and this can reduce mobility which extends in-patient time. An optimal analgesia regime is crucial to identify. Opioids produce effective pain relief but are associated with nausea, vomiting, and respiratory depression which can hinder physiotherapy and discharge. Finding alternatives has been of interest in recent years, particularly fascial blocks. These are anaesthetic injections beneath fascia which spread to nerves providing pain relief from surgery and are used with a general or spinal anaesthetic. Two of these blocks which are of interest to total hip arthroplasty are the quadratus lumborum block and fascia iliaca block. Studies have investigated the effectiveness of these blocks through patient factors, primarily pain scores, opioid consumption, and other secondary outcomes such as ambulation and length of stay. This review takes a narrative approach and investigates the literature around the topic. Pain and opioid consumption were the most widely reported outcomes, reported in 90% and 86% of studies. 83% of these studies reported positive effects on pain scores when FIB was utilised. 80% of these studies reported positive effects on opioid consumption when FIB was used. When QLB block was utilised, pain and opioid consumption were positively impacted in 82% of studies. This paper has been written with the intention of reviewing current literature to give an impression of the effectiveness of the blocks and propose potential areas for future work on the blocks.
FIELD: veterinary microbiology, biotechnology. SUBSTANCE: new strain Rodococcus equi VIEV N 2 shows all properties typical for Rodococcus genus. Strain administrated with bacterial vaccine for salmonellosis control in sheep decreases reactivity of salmonellae and stimulates antibody producing in organism with respect to the main pathogen. Strain can be used as an immunostimulating agent for vaccine making. EFFECT: new strain indicated above, enhanced effectiveness of strain. 1 tbl
Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
FIELD: hairdressing art. SUBSTANCE: human hair containing keratinous fibres maintained under mechanical tension are brought to contact with steam-containing gas, temperature of which is at least 75 C for period of time not longer than 2 minutes. Composition containing at least one silicone compound is applied onto hair during contact. Fibers thus-treated are then cooled, and mechanical means providing tension are removed from hair. EFFECT: hair thus-treated preserves beautiful curls for long time and acquires cosmetic properties of softness and smoothness. 14 cl
Based on findings from animal reproduction studies, LAMZEDE may cause embryo-fetal harm when administered to a pregnant female. Administration of velmanase alfa-tycv to pregnant rats during the period of organogenesis caused skeletal and visceral malformations. In rats and rabbits, skeletal and visceral malformations were observed at exposures that were approximately 7- and 2.5-fold, respectively, those observed in patients treated at the recommended dose of 1 mg/kg.

The decision to continue or discontinue LAMZEDE treatment during pregnancy should consider the female’s need for LAMZEDE, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease.

For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with LAMZEDE. Advise females of reproductive potential to use effective contraception during treatment with LAMZEDE and for 14 days after the last dose if LAMZEDE is discontinued [see Use in Specific Populations (8.1, 8.3)].
The invention discloses a compound medicine composition for improving oral bioavailability of paclitaxel and application of the compound medicine composition with the application number being 201110004638.9 and the application date being 2011.1.11. The invention discloses the compound medicine composition for improving oral bioavailability of paclitaxel and application of the compound medicine composition. The invention also discloses a medicine composition containing the compound medicine composition and a paclitaxel monomeric compound. The compound medicine composition provided by the invention can be used for improving the oral bioavailability of the paclitaxel, and is capable of improving an anticancer effect of the paclitaxel while being used for preparing an anticancer medicine. In the compound medicine composition, the paclitaxel is used as a main anticancer ingredient, the process of extracting the monomeric compound from the traditional Chinese medicine passes the first pass effect of inhibiting the paclitaxel, and therefore the oral bioavailability and the anticancer effect of the paclitaxel are improved. Experiments prove that the compound medicine composition is prepared into an oral medicine, and is capable of improving blood concentration and antitumor effect of the paclitaxel after taken.
Stimufend is administered subcutaneously via a single-dose prefilled syringe for manual use. 

Prior to use, remove the carton from the refrigerator and allow the Stimufend prefilled syringe to reach room temperature for a minimum of 30 minutes. Discard any prefilled syringe left at room temperature for greater than 72 hours. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Stimufend if discoloration or particulates are observed. 

The needle cap on the pre-filled syringes contains dry natural rubber (derived from latex); persons with latex allergies should not administer these products. 

Pediatric Patients weighing less than 45 kg

The Stimufend pre-filled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg). The syringe does not bear graduation marks, which are necessary to accurately measure doses of Stimufend less than 0.6 mL (6 mg) for direct administration to patients. Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1.
Background: It has been shown that the decrease of the range of motion in the ankle, due to the presence of latent trigger points in the gastro-sole complex, can affect performance, as well as being a predisposing factor to injury. Objective: To compare the effects of Dry Needling and Foam roller in healthy athletes with limited dorsal ankle flexion by the presence of latent trigger points. Material and methods: This is a clinical trial, single-blind experimental study. The sample will have a total of 44 students, volunteers, healthy of the degree of physiotherapy of the the investigator's university (UCV). Participants who meet the inclusion criteria will be randomly assigned in two groups: Group 1 or Dry Needling (N = 22) and Group 2 or Foam Roller (N = 22). The range of motion of ankle will be assessed through the Leg Motion system (Check Your Motion®, Albacete, Spain). Assessed thought Ankle Test (post-intervention and 24 hours later). The reference values to consider the decreased ankle ROM will be \<11.5 cm, \<35º measured with Easy Angle® digital goniometer (Meloq AB, Sweden) and/or if it has a difference of 1.5 cm between both extremities. Thus, the effect on previous activity performance will be assessed thought the Counter Movement Jump. Data analysis: Once the distribution of the sample is determined, a descriptive analysis of the data will be carried out and an ANOVA of repeated measures. Will be used to compare the data found in the two groups that make up the study taking into account a 95% CI and an error less than 0.05.
The present invention provides an active binding sequence of mammalian alpha- fetoprotein (AFP) to the receptor of AFP (AFPr or RECAP). The sequence is embodied in peptides comprising Lys-Glx-Glx-Xaa-Leu-Ile-Asn (SEQ. ID. NO: 1) and variants thereof, wherein GIx means GIn or GIu, each GIx being selected independently of the other, and Xaa represents Phe or Leu. The peptides bind a site of the AFP receptor. This peptide can be used as a substitute for AFP in the detection, purification and imagining of RECAF. This peptide, as it binds to RECAF which is elevated in cancer cells, allows for a method of diagnostic determination of cancer or chemotherapeutic delivery using cytotoxic or radiological agents.